

Resource Summary Report

Generated by [kravitz2](#) on Aug 23, 2026

Mutect2

RRID:SCR_026692

Type: Tool

Proper Citation

Mutect2 (RRID:SCR_026692)

Resource Information

URL: <https://gatk.broadinstitute.org/hc/en-us/articles/360037593851-Mutect2>

Proper Citation: Mutect2 (RRID:SCR_026692)

Description: Software tool to call somatic short mutations via local assembly of haplotypes. Somatic variant caller that uses local assembly and realignment to detect SNVs and indels.

Resource Type: software application, software resource

Defining Citation: [DOI:10.1101/861054](https://doi.org/10.1101/861054)

Keywords: Somatic variant caller, call somatic short mutations, detect SNVs and indels,

Resource Name: Mutect2

Resource ID: SCR_026692

Record Creation Time: 20250401T060330+0000

Record Last Update: 20260821T043143+0000

Ratings and Alerts

No rating or validation information has been found for Mutect2.

No alerts have been found for Mutect2.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1271 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1835.

Pregnall AM, et al. (2026) Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution. *NPJ precision oncology*, 10(1).

Zhang J, et al. (2026) Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth. *iScience*, 29(2), 114786.

Kryeziu K, et al. (2026) Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity. *Cell reports. Medicine*, 7(6), 102840.

Kawazu M, et al. (2026) Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges. *Cancer research communications*, 6(4), 961.

Voorthuis RAB, et al. (2026) PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(10), 1983.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. *Cancer immunology research*, 14(5), 771.

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1434.

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. *Cancer research*, 86(4), 1073.

Wang C, et al. (2026) A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations. *Cancer research*, 86(12), 3074.

Yu K, et al. (2026) Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(10), 1946.

Takahashi J, et al. (2026) Spatial Multiomic Analyses Reveal Carcinogenic Pathways in End-Stage Renal Disease. *Cancer discovery*, 16(3), 478.

Huffman BM, et al. (2026) A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1666.

Buckley KH, et al. (2026) Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential. *Molecular cancer research : MCR*, 24(7), 589.

van der Elst A, et al. (2026) Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2732.

Andersen L, et al. (2026) Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes. *Cancer research communications*, 6(4), 811.

Zhou X, et al. (2026) Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in *Candida albicans*. *PLoS biology*, 24(2), e3003631.

Krishna A, et al. (2026) Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling. *Nature genetics*, 58(2), 366.

Valentín López JC, et al. (2026) Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2413.

Li C, et al. (2026) Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancer. *Research square*.